Introduction {#section5-1753466618821038}
============

Acute respiratory distress syndrome (ARDS) is a life-threatening form of respiratory failure associated with a mortality rate of approximately 40--45%.^[@bibr1-1753466618821038],[@bibr2-1753466618821038]^ As several studies have demonstrated the benefits of extracorporeal membrane oxygenation (ECMO) in patients with ARDS who are unresponsive to conventional management, ECMO is emerging as a potential therapeutic modality, and its use in clinical practice is increasing.^[@bibr3-1753466618821038][@bibr4-1753466618821038]--[@bibr5-1753466618821038]^ However, ECMO is still a complex and costly treatment that can be exposed to several significant complications. Therefore, efforts have been made to identify patients who are more likely to survive after ECMO support.

Bacterial pneumonia is a predominant etiology of acute respiratory failure requiring ECMO.^[@bibr5-1753466618821038]^ Pneumonia is classified as community-acquired pneumonia (CAP) or hospital-acquired pneumonia (HAP). CAP and HAP require different therapeutic approaches, because different causative pathogens are involved.^[@bibr6-1753466618821038],[@bibr7-1753466618821038]^ Some studies suggest that CAP and HAP should be regarded as distinct clinical entities since they have different clinical courses.^[@bibr8-1753466618821038],[@bibr9-1753466618821038]^

Although bacterial pneumonia is regarded as a favorable factor for survival after ECMO support,^[@bibr10-1753466618821038]^ it is unknown whether type of pneumonia (CAP or HAP) should be considered when predicting outcomes for ARDS patients treated with ECMO. The objective of this study was to identify clinical, bacteriological, and treatment characteristics in pneumonia patients who received ECMO for respiratory support according to type of pneumonia and to compare clinical outcomes between groups.

Methods {#section6-1753466618821038}
=======

Study design and sample {#section7-1753466618821038}
-----------------------

This observational study was conducted at Samsung Medical Center (a 1989-bed, university-affiliated, tertiary referral hospital in Seoul, South Korea) between January 2012 and December 2016. We included adult patients over 18 years of age who were diagnosed with ARDS caused by bacterial pneumonia and received ECMO for respiratory support during the study period. Patients under 18 years of age, in whom other pathogens (e.g. virus or fungus) were identified, who lacked microbial identification, or who were transferred from other hospitals after ECMO initiation were excluded from this study. Eligible patients were divided into two groups according to type of pneumonia, CAP or HAP. The study was approved by the Institutional Review Board of Samsung Medical Center (approval no: 2017-07-075), which waived the need for informed consent because of the retrospective observational nature of the study. All patient data were anonymized and de-identified before analysis.

Diagnosis and management of pneumonia ARDS {#section8-1753466618821038}
------------------------------------------

Pneumonia was diagnosed when we detected new radiographic infiltrates with at least two of the following clinical criteria: fever or hypothermia, new cough with or without sputum production, pleuritic chest pain, dyspnea, and altered breath sounds on auscultation.^[@bibr11-1753466618821038]^ If a patient was clinically suspected or diagnosed with pneumonia, empirical antibiotic therapy was initiated according to standard guidelines.^[@bibr6-1753466618821038],[@bibr7-1753466618821038]^ We classified pneumonia cases into two categories: CAP for pneumonia that occurred or developed outside of the hospital setting and HAP for pneumonia that occurred ⩾2 days after hospitalization and was not incubating at the time of hospital admission.^[@bibr6-1753466618821038]^ According to the Berlin definition, ARDS was defined as follows: onset within 1 week of a known clinical insult or new or worsening respiratory symptoms; bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules; respiratory failure not fully explained by cardiac failure or fluid overload and requiring objective assessment to exclude hydrostatic edema if no risk factor is present; and partial arterial oxygen concentration/inspired oxygen faction (PaO~2~/FiO~2~) ratio ⩽ 300 mmHg with positive end-expiratory pressure or continuous positive airway pressure ⩾ 5 cmH~2~O.^[@bibr1-1753466618821038]^

Management of mechanical ventilation (MV) was performed according to the protocol proposed by the ARDS Network as much as possible.^[@bibr12-1753466618821038],[@bibr13-1753466618821038]^ When patients could not maintain adequate oxygenation or carbon dioxide removal with MV, adjunctive therapies such as inhaled nitric oxide, prone positioning, and glucocorticosteroid therapy were also used at the discretion of the physician.

Initiation and management of ECMO {#section9-1753466618821038}
---------------------------------

Patient selection, medical management, and settings of the MV and ECMO circuits followed institutional protocols that have been described previously.^[@bibr14-1753466618821038]^ Patients with deteriorating hypoxemia (PaO~2~/FiO~2~ ratio \< 80 on FiO~2~ \> 90%) or uncompensated hypercapnia (CO~2~ retention with pH \< 7.20 despite plateau pressure \> 30 cmH~2~O) under advanced mechanical ventilator support with or without adjunctive therapies were considered for ECMO support. The final decisions regarding ECMO initiation were made after consultation with a multidisciplinary ECMO team consisting of intensivists, pulmonologists, and cardiothoracic surgeons.

Pump blood flow and sweep gas flow rates were adjusted to maintain target oxygen saturation and carbon dioxide removal rate at all times. During ECMO support, pressure controlled ventilation mode was used for patients with FiO~2~ lower than 30%, respiratory rate lower than 10--12 per minute, positive end-expiratory airway pressure of 10 cmH~2~O, and peak inspiratory pressure of 20--25 cmH~2~O to achieve low tidal ventilation (\< 5 ml/kg of predicted body weight) and prevent ventilator-induced lung injury. If patients were stable and tolerant of treatment, we changed the mode of MV to pressure support ventilation and subsequently adjusted ventilator settings for weaning. The possibility of weaning from ECMO was assessed daily, and trial off was performed to determine decannulation when arterial blood gas was maintained within the target range with a sweep gas flow of 1 l/min or less regardless of pump blood flow at acceptable ventilator settings. Patients who maintained adequate gas exchange without sweep gas flow (sweep gas off trial) were closely monitored for at least 2 h and decannulation was considered for patients who were stable during this period. The decision about total duration of weaning trial and decannulation were made by treating intensivists and an ECMO team.

Data collection and clinical outcomes {#section10-1753466618821038}
-------------------------------------

We retrospectively reviewed and obtained clinical and laboratory data from our institution\`s ECMO database, which prospectively registered all patients who were treated with ECMO since 2012. Acute physiology and chronic health evaluation (APACHE) II score, sequential organ failure assessment (SOFA) score, and lung injury score were estimated by the worst value within the first 24 h in the intensive care unit (ICU) admission. For prediction of survival after ECMO support, the respiratory extracorporeal membrane oxygenation survival prediction (RESP) score^[@bibr10-1753466618821038]^ and predicting death for severe ARDS on VV ECMO (PRESERVE) score^[@bibr15-1753466618821038]^ were calculated on the first day of ECMO support. Driving pressure was calculated as peak inspiratory pressure minus positive end-expiratory pressure because all patients underwent ventilation with pressure-control mode in which the peak pressure can be used as a surrogate for plateau pressure.^[@bibr16-1753466618821038]^

An etiological diagnosis was considered when a respiratory pathogen was isolated from a usually sterile specimen, pneumococcal antigen was detected in urine, or a predominant microorganism was isolated from adequate sputum or bronchial washing fluids with compatible Gram staining, as previously reported.^[@bibr17-1753466618821038]^ Multidrug resistant (MDR) pathogens were identified by an international expert proposal for interim standard definitions for acquired resistance,^[@bibr18-1753466618821038]^ which is nonsusceptible to at least one agent in three antimicrobial categories. The appropriateness of antibiotic therapy was analyzed for all cases with etiological diagnoses according to susceptibility test criteria for lower respiratory tract pathogens. Antibiotic therapy was classified as inappropriate if the initially prescribed antibiotics were not active against the identified pathogens based on *in vitro* susceptibility testing.^[@bibr19-1753466618821038]^ The antibiotic treatments for pneumonia were in line with the clinical practice guidelines by the Infectious Diseases Society of America/American Thoracic Society,^[@bibr6-1753466618821038],[@bibr7-1753466618821038]^ and the adequacy of antibiotics therapy, including the appropriateness of antibiotics selection, dosing, and duration were routinely assessed by infectious disease specialists in our hospital. We usually administered antibiotics active against the identified pathogens for 7--10 days, but sometimes longer duration of antibiotics might be indicated, depending upon the rate of improvement of clinical, radiologic, and laboratory parameters.

The primary outcome in this study was survival to discharge from hospital. Secondary outcomes were success of weaning from MV and ECMO, duration of ECMO support, appropriateness of antibiotic therapy, ECMO-related complications, and 30-day and 90-day mortality after ECMO initiation. We identified data related to clinical outcomes by review of hospital medical records.

Statistical analyses {#section11-1753466618821038}
--------------------

The data are presented as median and interquartile range for continuous variables and as number (percent) for categorical variables. The data were analyzed using Kolmogorov--Smirnov tests for normal distribution. The Mann--Whitney *U* test was used to compare continuous variables, and the Chi-squared and Fisher's exact tests were used to compare categorical variables. A *p* value \<0.05 was considered statistically significant. To estimate whether type of pneumonia was associated with survival to discharge, we performed multivariable logistic regression analysis to adjust for age, sex, type of pneumonia, and factors with *p* \< 0.2 on univariate analysis. All data were analyzed using SPSS version 21.0 (SPSS Inc., Chicago, IL, USA).

Results {#section12-1753466618821038}
=======

Patient baseline characteristics {#section13-1753466618821038}
--------------------------------

During the study period, a total of 136 patients were identified as having bacterial pneumonia-induced ARDS and receiving VV ECMO support. We excluded 50 patients lacked microbial identification, 13 patients transferred from other hospitals after ECMO initiation, 12 patients with nonbacterial pathogens, and 5 patients under 18 years of age ([Figure 1](#fig1-1753466618821038){ref-type="fig"}). Thus, 56 bacterial pneumonia patients with ARDS receiving VV ECMO were included in this study. The baseline characteristics and clinical features of the two groups are presented in [Table 1](#table1-1753466618821038){ref-type="table"}. There were 21 patients (37.5%) with CAP and 35 patients (62.5%) with HAP. The patients with HAP were older, more likely to be male, and had higher body mass index. However, these differences were not significant. Comorbidities, such as malignancy, chronic lung disease, diabetes, neurologic disease, cardiovascular disease, and chronic kidney disease, were not significantly different between the two groups. APACHE II (22.0 *versus* 22.5, *p* = 0.382) and SOFA scores (8 *versus* 8, *p* = 0.893) were not different between the two groups. In addition, vasoactive-inotropic (4 *versus* 3, *p* = 0.417) and lung injury scores (2.84 *versus* 2.67, *p* = 0.107) were not different between the two groups at the time of ICU admission.

![Study flow diagram.\
ARDS, acute respiratory distress syndrome; CAP, community-acquired pneumonia; ECMO, extracorporeal membrane oxygenation; HAP, hospital-acquired pneumonia; VV, venovenous.](10.1177_1753466618821038-fig1){#fig1-1753466618821038}

###### 

Baseline characteristics of patients with pneumonia receiving venovenous extracorporeal membrane oxygenation.

![](10.1177_1753466618821038-table1)

  Characteristics                   Total (*N* = 56)       CAP (*n* = 21)       HAP (*n* = 35)      *p* value
  --------------------------------- ---------------------- -------------------- ------------------- -----------
  Age, years                        58.50 (50.50--67.00)   55 (49--71)          62 (50--67)         0.850
  Sex, male                         42 (75.0)              15 (71.4)            27 (77.1)           0.752
  BMI, kg/m^2^                      23.45 (20.55--25.4)    23.3 (19.3--25.35)   23.5 (22.1--25.4)   0.340
  Transferred from other hospital   15 (26.8)              6 (28.6)             9 (25.7)            0.336
  Co-morbidity                                                                                      
   Malignancy                       16 (28.6)              6 (28.6)             10 (28.6)           \>0.999
   Chronic lung disease             22 (39.3)              5 (23.8)             17 (48.6)           0.092
   Diabetes                         14 (25.0)              6 (10.7)             8 (22.9)            0.752
   Neurologic disease               2 (3.6)                1 (4.8)              1 (2.9)             \>0.999
   Cardiovascular disease           3 (5.4)                1 (4.8)              2 (5.7)             0.740
   Chronic kidney disease           7 (12.5)               1 (4.8)              6 (17.1)            0.237
  APACHE II score                   22.0 (16.6--28.8)      22.0 (19.0--28.5)    22.5 (15.0--29.5)   0.382
  SOFA score                        8 (5--13)              8 (5--15)            8 (4--13)           0.893
  Renal replacement therapy         13 (23.2)              5 (23.8)             8 (22.9)            0.790
  Vasoactive-inotropic score        3 (1--4)               4 (3--4)             3 (0--4)            0.417
  Lung injury score                 2.67 (2.44--3.50)      2.84 (2.00--3.33)    2.67 (2.33--3.50)   0.107

Values are given as median (interquartile range) or number (%).

APACHE, Acute Physiology and Chronic Health Evaluation; BMI, body mass index; CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia; SOFA, sequential organ failure assessment.

Medical management prior to ECMO {#section14-1753466618821038}
--------------------------------

Treatment modalities for patients in severe respiratory failure with pneumonia prior to ECMO initiation are presented in [Table 2](#table2-1753466618821038){ref-type="table"}. The duration of MV prior to initiation of ECMO was similar in the CAP and HAP groups. Measurements performed during MV prior to ECMO, including positive end-expiratory pressure, peak inspiratory pressure, driving pressure, tidal volume per predicted body weight, and worst values of arterial blood gases, were not different between the two groups. Adjunctive or rescue therapies for severe respiratory failure including steroids, neuromuscular blocking agents, prone positioning, and inhaled nitric oxide were similar between the two groups. Finally, RESP and PRESERVE scores were similar between the two groups.

###### 

Medical management prior to venovenous extracorporeal membrane oxygenation.

![](10.1177_1753466618821038-table2)

  Medical management                    Total (*N* = 56)       CAP (*n* = 21)         HAP (*n* = 35)          *p* value
  ------------------------------------- ---------------------- ---------------------- ----------------------- -----------
  Duration of MV before ECMO, days      7.58 (5.35--12.14)     7.11 (5.25--9.33)      7.85 (5.92--13.22)      0.542
   \< 2 days                            22 (39.3)              9 (42.9)               13 (37.1)               0.780
   2--7 days                            18 (32.1)              6 (28.3)               12 (34.3)               0.551
   \> 7 days                            16 (28.6)              6 (28.6)               10 (28.6)               \>0.999
  Pre-ECMO treatment                                                                                          
   NMBA                                 30 (53.6)              11 (52.4)              19 (54.3)               0.511
   Nitric oxide                         10 (17.9)              6 (28.6)               4 (7.1)                 0.152
   Prone position                       6 (10.7)               3 (14.3)               3 (8.6)                 0.661
   Steroid                              7 (12.5)               3 (14.3)               4 (7.1)                 0.734
  Pre-ECMO MV setting                                                                                         
   PaO~2~/FiO~2~                        74.4 (54.6--92.0)      71.05 (53.15--88.99)   76.45 (55.53--96.87)    0.287
   PEEP, cmH~2~O                        10.00 (5.00--12.00)    10.00 (5.75--12.25)    9.00 (5.00--11.50)      0.246
   Minute volume, l/min                 9.00 (7.40--10.73)     10.45 (7.30--13.03)    8.80 (7.48--9.28)       0.114
   Tidal volume/PBW, ml/kg              7.2 (5.2--9.2)         7.2 (5.4--9.0)         7.1 (5.0--9.3)          0.125
   Peak inspiratory pressure, cmH~2~O   30.00 (24.75--32.00)   30.00 (24.75--33.25)   28.50 (22.75-- 30.00)   0.454
   Respiratory rate, breaths/min        24.00 (20.00--27.75)   25.00 (21.50--32.00)   22.00 (20.00-- 25.75)   0.080
   Driving pressure, cmH~2~O            16.00 (14.00--20.00)   16.00 (14.00--20.00)   15.00 (14.00--20.00)    0.544
  Pre-ECMO blood gas                                                                                          
   pH                                   7.259 (7.127--7.362)   7.259 (7.127--7.362)   7.264 (7.127-- 7.422)   0.334
   PaCO~2~, mmHg                        59.9 (49.8--73.5)      59.9 (49.8--73.5)      58.6 (47.9--73.5)       0.768
   PaO~2~, mmHg                         59.1 (53.4--70.0)      59.1 (53.4--70.0)      58.7 (52.8--70.0)       0.008
   HCO~3~^−^, mmol/l                    26.0 (22.7--30.5)      26.0 (22.7--30.5)      26.5 (23.0--30.5)       0.084
   SaO~2~, %                            86.8 (82.6--91.3)      86.9 (82.6--91.3)      86.7 (82.1--91.3)       \>0.999
  RESP score                            0.00 (−1.00--2.00)     0.00 (−1.50--2.00)     1.00 (−1.00--3.00)      0.179
  PRESERVE score                        4.50 (3.00--6.75)      4.00 (2.50--6.00)      5.00 (4.00--7.00)       0.107

Values are given as median (interquartile range) or number (%).

ARDS, acute respiratory distress syndrome; CAP, community-acquired pneumonia; ECMO, extracorporeal membrane oxygenation; FiO2, fraction of inspired oxygen; HAP, hospital-acquired pneumonia; MV, mechanical ventilation; NMBA, neuromuscular blocking agents; PaCO2, partial pressure of carbon dioxide in arterial blood; PaO2, partial pressure of oxygen in arterial blood; PBW, predictive body weight; PEEP, positive end-expiratory pressure; PRESERVE, predicting death for severe ARDS on venovenous ECMO; RESP, respiratory extracorporeal membrane oxygenation survival prediction; SaO2, arterial oxygen saturation.

Laboratory and microbiologic characteristics {#section15-1753466618821038}
--------------------------------------------

As shown in [Table 3](#table3-1753466618821038){ref-type="table"}, laboratory findings were not different between the two groups. The distributions of pathogens are shown in [Table 3](#table3-1753466618821038){ref-type="table"}. The most common pathogens were *Streptococcus pneumonia* in the CAP group (*n* = 12, 57.1%) and *Acinectobacter baumanii* in the HAP group (*n* = 13, 37.1%). The presence of MDR pathogens was more common in patients with HAP than in those with CAP; however, these findings were not significantly different between the two groups (57.1% *versus* 74.3%, *p* = 0.125). In addition, the appropriateness of initial antibiotic therapy was not different (66.7% *versus* 60.0%, *p* = 0.843).

###### 

Laboratory and microbiologic characteristics in the patients with pneumonia receiving venovenous extracorporeal membrane oxygenation.

![](10.1177_1753466618821038-table3)

  Characteristics                              Total (*N* = 56)         CAP (*n* = 21)           HAP (*n* = 35)            *p* value
  -------------------------------------------- ------------------------ ------------------------ ------------------------- -----------
  Laboratory parameters                                                                                                    
  Lactic acid, mmol/l                                                                                                      
   Pre-ECMO                                    3.07 (1.67--4.49)        3.91 (1.78--6.74)        2.83 (1.42--3.26)         0.119
   Post-ECMO 6 h                               3.18 (1.95--5.86)        3.32 (2.42--11.37)       2.84 (1.70--4.59)         0.174
   Post-ECMO 24 h                              2.13 (1.56--2.95)        2.23 (1.71--6.24)        1.99 (1.26--2.68)         0.111
   Post-ECMO 48 h                              1.93 (1.38-- 2.78)       2.14 (1.73--4.59)        1.69 (1.17--2.67)         0.068
   WBC, 10^3^/ml                               14.49 (8.73--20.13)      13.22 (7.16--19.22)      15.45 (10.88--20.04)      0.273
   Platelet, 10^3^/ml                          151.04 (52.00--210.25)   134.61 (41.75--183.75)   192.28 (90.75-- 204.75)   0.089
   Total bilirubin, mg/dl                      1.60 (0.50--1.75)        1.50 (0.50--1.82)        1.73 (0.40--1.80)         0.865
   Creatinine, mg/dl                           1.59 (0.68--1.86)        1.71 (0.75--1.94)        1.22 (0.61--1.64)         0.391
   CRP, mg/dl                                  5.55 (2.69--13.74)       4.17 (1.32--10.25)       6.73 (2.25--15.64)        0.643
   Procalcitonin, ng/ml                        2.35 (0.45--7.35)        2.05 (0.15--6.25)        2.55 (0.50--8.94)         0.873
  Microbiologic parameters                                                                                                 
  Culture positive specimen                                                                                                
   Trans-tracheal aspirate                     44 (78.6)                17 (81.0)                27 (77.1)                 0.932
   Blood                                       16 (28.6)                9 (42.9)                 7 (20.0)                  0.104
   Broncho-alveolar lavage fluid               8 (14.3)                 3 (14.3)                 5 (14.3)                  \>0.999
   Pleural fluid                               5 (8.9)                  2 (9.5)                  3 (8.8)                   0.765
  Microbiologic results                                                                                                    
   Gram-positive pathogens                                                                                                 
   *CN Staphylococcus*                         3 (5.4)                  1 (4.8)                  2 (5.7)                   
   *Enterococcus faecium*                      1 (1.8)                  1 (4.8)                  0 (0)                     
   *Kocuria kristinae*                         2 (3.6)                  0 (0)                    2 (5.7)                   
   *MRSA*                                      7 (12.5)                 2 (9.5)                  5 (14.3)                  
   *Staphylococcus aureus*                     1 (1.8)                  0 (0)                    1 (2.9)                   
   *Streptococcus mitis*                       1 (1.8)                  0 (0)                    1 (2.9)                   
   *Streptococcus pneumonia*                   17 (30.4)                12 (57.1)                5 (14.3)                  
  Gram-negative pathogens                                                                                                  
   *Acinetobacter baumanii*                    18 (32.1)                5 (23.8)                 13 (37.1)                 
   *Escherichia coli*                          2 (3.6)                  1 (4.8)                  1 (2.9)                   
   *Enterobacter aerogenes*                    2 (3.6)                  1 (4.8)                  1 (2.9)                   
   *Klebsiella pneumonia*                      3 (5.4)                  2 (9.5)                  1 (2.9)                   
   *Mycoplasma pneumonia*                      1 (1.8)                  1 (4.8)                  0 (0)                     
   *Prevotella bivia*                          1 (1.8)                  0 (0)                    1 (2.9)                   
   *Pseudomonas aeruginosa*                    6 (10.7)                 4 (19.0)                 2 (5.7)                   
   *Serratia marcescens*                       1 (1.8)                  1 (4.8)                  0 (0)                     
   *Stenotrophomonas maltophilia*              3 (5.4)                  2 (9.5)                  1 (2.9)                   
  Occurrence of MDR pathogen                   38 (67.9)                12 (57.1)                26 (74.3)                 0.125
  Inappropriate initial antibiotic treatment   21 (37.5)                7 (33.3)                 14 (40.0)                 0.843

Values are given as median (interquartile range) or number (%).

CAP, community-acquired pneumonia; CN, coagulase negative; CRP, C-reactive protein; ECMO, extracorporeal membrane oxygenation; HAP, hospital-acquired pneumonia; MDR, multidrug resistance; MRSA, methicillin-resistant *S. aureus*; WBC, white blood cell.

Medical management after ECMO initiation {#section16-1753466618821038}
----------------------------------------

Treatment modalities during the first 72 h after ECMO initiation are presented in [Table 4](#table4-1753466618821038){ref-type="table"}. The post-ECMO MV setting was similar in the CAP and HAP groups. In addition, the need for organ supports such as vasopressors and renal replacement therapy were not different. Finally, SOFA scores during the first 72 h after ECMO initiation were not different between the two groups.

###### 

Managements during the first 72 hours after initiation of venovenous extracorporeal membrane oxygenation.

![](10.1177_1753466618821038-table4)

  ------------------------------------------------------------------------------------------------------
  Medical management                    Total (*N* = 56)   CAP (*n* = 21)   HAP (*n* = 35)   *p* value
  ------------------------------------- ------------------ ---------------- ---------------- -----------
  Post-ECMO MV setting                                                                       

   PaO~2~/FiO~2~                        81 (61--99)        79 (59--99)      81 (62--99)      0.455

   PEEP, cmH~2~O                        9 (6--12)          9 (6--12)        9 (5--12)        0.358

   Tidal volume/ PBW, ml/kg             7.2 (5.2--9.2)     7.2 (5.4--9.0)   7.1 (5.0--9.3)   0.125

   Peak inspiratory pressure, cmH~2~O   25 (17--28)        25 (17--28)      25 (18--29)      0.367

   Respiratory rate, breaths/min        22 (18--26)        22 (19--26)      21 (18--25)      0.175

   Driving pressure, cmH~2~O            15 (13--17)        16 (13--17)      15 (13--17)      0.322

  Acute kidney injury\                  5 (8.9)\           2 (9.5)\         3 (8.6)\         0.765\
  Renal replacement therapy             2 (3.6)            1 (4.8)          1 (2.9)          0.190

  Vasopressors                          6 (10.7)           3 (14.3)         3 (8.6)          0.661

  SOFA score                            10 (5--17)         11 (4--17)       10 (5--18)       0.623
  ------------------------------------------------------------------------------------------------------

CAP, community-acquired pneumonia; ECMO, extracorporeal membrane oxygenation; FiO2, fraction of inspired oxygen; HAP, hospital-acquired pneumonia; PaCO2, partial pressure of carbon dioxide in arterial blood; PaO2, partial pressure of oxygen in arterial blood; PBW, predictive body weight; PEEP, positive end-expiratory pressure; SOFA, sequential organ failure assessment.

Clinical outcomes {#section17-1753466618821038}
-----------------

Clinical outcomes of patients with bacterial pneumonia-induced ARDS who received VV ECMO support are given in [Table 5](#table5-1753466618821038){ref-type="table"}. Of 56 patients, 2 patients (3.6%) required conversion to venoarterial ECMO because of hemodynamic instability due to right ventricular failure and 36 patients (64.3%) died during the hospitalization. Multi-organ failure related with severe pneumonia was the leading cause of death in both CAP and HAP groups (57.1% *versus* 54.5%, *p* = 0.780). In addition, death due to an ECMO-related complication occurred in eight patients (21.4% *versus* 22.7%, *p* = 0.342). However, survival to hospital discharge, the primary endpoint in this study, was not different between the two groups (38.1% *versus* 37.1%, *p* \> 0.999). In addition, other clinical outcomes including weaning from MV and ECMO, ECMO-related complications, 30-day mortality, and 90-day mortality were similar in the CAP and HAP groups. Duration of MV and ECMO and lengths of ICU and hospital stays were not different between the two groups. Univariable analysis and multivariable logistic regression analysis were used to identify variables for survival to discharge that had significant prognostic value in [Table 6](#table6-1753466618821038){ref-type="table"}. There were no significantly and independently variables associated with survival to discharge.

###### 

Clinical outcomes of the patients with pneumonia receiving venovenous extracorporeal membrane oxygenation.

![](10.1177_1753466618821038-table5)

  Clinical outcomes                         Total (*N* = 56)       CAP (*n* = 21)         HAP (*n* = 35)         *p* value
  ----------------------------------------- ---------------------- ---------------------- ---------------------- -----------
  Survival to hospital discharge            20 (35.7)              7 (33.3)               13 (37.1)              \>0.999
  MV duration after ECMO initiation, days   3.0 (1.0--4.5)         3.5 (1.0--5.0)         3.0 (1.0--4.5)         0.454
  Conversion to VA ECMO                     2 (3.6)                1 (4.8)                1 (2.9)                0.190
  MV weaning success                        23 (41.1)              7 (33.3)               16 (45.7)              0.152
  ECMO weaning success                      26 (46.4)              10 (47.6)              16 (45.7)              \>0.999
  ECMO duration, days                       13.75 (5.55--29.40)    14.00 (4.50--39.50)    13.00 (6.00--25.00)    0.582
  ECMO-related complication                 15 (26.8)              6 (28.6)               9 (25.7)               0.355
  Oxygenator failure                        5 (8.9)                2 (9.5)                3 (8.6)                
  Cannula site bleeding                     3 (5.4)                1 (4.8)                2 (5.7)                
  Limb ischemia                             2 (3.6)                1 (4.8)                1 (2.9)                
  Hemolysis                                 3 (5.4)                1 (4.8)                2 (2.9)                
  Stroke                                    2 (3.6)                1 (4.8)                1 (2.9)                
  ICU LOS, days                             26.00 (15.75--35.50)   26.00 (15.75--35.50)   26.00 (14.75--35.50)   0.733
  Hospital LOS, days                        39.50 (19.75--56.00)   39.50 (19.75--56.00)   40.50 (19.50--56.00)   0.828
  30-day mortality                          22 (39.3)              9 (42.9)               13 (23.2)              0.780
  90-day mortality                          35 (62.5)              14 (66.7)              21 (60)                \>0.999

Values are given as median (interquartile range) or number (%).

CAP, community-acquired pneumonia; ECMO, extracorporeal membrane oxygenation; HAP, hospital-acquired pneumonia; LOS, length of stay; MV, mechanical ventilation; VA, venoarterial.

###### 

Univariable and multivariable logistic regression analysis for clinical variables associated with survival to discharge in study patients.
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  Variable                    Univariable   Multivariable                                
  --------------------------- ------------- --------------- ------------ -------- ------ --------------
  Age                         0.1608        0.97            0.93--1.01   0.5797   0.12   0.00--222.87
  SOFA score                  0.1420        0.90            0.78--1.04   0.6577   1.08   0.78--1.48
  Pre-ECMO nitric oxide       0.1903        0.33            0.06--1.73   0.4389   0.36   0.03--4.81
  Pre-ECMO respiratory rate   0.1037        1.11            0.98--1.26   0.0523   1.31   1.00--1.72
  RESP score                  0.0604        1.25            0.99--1.59   0.9278   0.98   0.63--1.51
  PRESERVE score              0.0608        0.77            0.58--1.01   0.5237   0.84   0.50--1.42

ARDS, acute respiratory distress syndrome; CI, confidence interval; ECMO, extracorporeal membrane oxygenation; OR, odds ratio; PRESERVE, predicting death for severe ARDS on venovenous ECMO; RESP, respiratory ECMO survival prediction; SOFA, sequential organ failure assessment.

Discussion {#section18-1753466618821038}
==========

In this study, we investigated whether clinical outcomes differed between CAP and HAP in ARDS patients treated with ECMO. Our results demonstrate that patients with bacterial pneumonia requiring ECMO for respiratory support have high mortality regardless of pneumonia category. Furthermore, lengths of ICU and hospital stays, as well as weaning rates from MV and ECMO, were not different between patients with CAP and HAP.

Patients with advanced age, malnutrition, immunosuppression, and severe acute or chronic illness have increased risks of developing HAP.^[@bibr20-1753466618821038],[@bibr21-1753466618821038]^ These factors are also associated with increased mortality, regardless of the category of pneumonia.^[@bibr22-1753466618821038]^ Therefore, patients with HAP are expected to have worse prognoses than patients with CAP. This view is supported by the findings of a previous study, in which the incidence of complications and the need for intensive care were higher in patients with HAP compared with patients with CAP.^[@bibr8-1753466618821038]^ Venditti and colleagues also reported that patients with HAP had higher pneumonia severity index and SOFA scores, longer hospital stays, and higher hospital mortality than patients with CAP.^[@bibr9-1753466618821038]^ However, they excluded ICU patients from their analysis; therefore, their cohort was characterized by significantly less severe disease than the patients included in our study.

In other studies including patients admitted to ICUs, severity of illness did not differ between CAP and HAP.^[@bibr22-1753466618821038][@bibr23-1753466618821038]--[@bibr24-1753466618821038]^ Furthermore, there were no differences in mortality rates according to the category of pneumonia, consistent with our results. Although the risk of organ failure including ARDS is high in patients with HAP, the category of pneumonia does not affect prognosis in critically ill patients with bacterial pneumonia, in whom organ failure requiring mechanical support has already developed. Therefore, type of pneumonia should not be considered when making treatment decisions for patients with ARDS caused by bacterial pneumonia who are to be placed on ECMO.

In critically ill patients with pneumonia, inappropriate antibiotic treatment is related to higher mortality.^[@bibr25-1753466618821038][@bibr26-1753466618821038]--[@bibr27-1753466618821038]^ Patients with HAP are more likely to be exposed to antibiotic-resistant bacteria than patients with CAP and therefore are at risk of inappropriate initial empiric antibiotic treatment based on microbiological characteristics.^[@bibr6-1753466618821038]^ In the present study, however, the rates of MDR pathogen occurrence were similar between CAP and HAP groups. In addition, the appropriateness of initial antibiotic therapy did not differ. These findings could help explain why we observed no differences in clinical outcomes between the two groups.

Although this study provides new information regarding outcome prediction in pneumonia patients with ARDS receiving ECMO support, it also has some limitations that should be considered. First, because it was conducted as a retrospective cohort study, there is always the possibility that selection bias influenced the significance of our findings. However, the data were prospectively collected from all patients who consecutively received ECMO support for ARDS caused by bacterial pneumonia at our institution. Nonetheless, limited number of patients enrolled might not be sufficiently powered to detect a significant difference between the groups. Second, our study was based at a single institution with a multidisciplinary ECMO team,^[@bibr14-1753466618821038]^ which could limit the generalizability of our findings to other hospitals. Finally, patients with culture-negative results were excluded from the study. Thus, the true incidence of MDR pathogens and their effects on outcomes may be underestimated.

In summary, patients with severe acute respiratory failure requiring ECMO for respiratory support suffered severe disease regardless of whether they were diagnosed with CAP or HAP, and there were no significant differences in weaning rates from ECMO and survival according to the category of pneumonia.
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